Industrial sector

Oligon Therapeutics Inc.

Oligon Therapeutics is an emerging biotechnology company based in Montreal, focused on developing a novel class of multimodal RNA therapeutics for the treatment of cancer, immunological disorders, and other complex diseases.

Powered by its proprietary SeekR technology platform, Oligon integrates dual RNA aptamer binders with dual siRNA silencers into a single, self-delivering oligonucleotide drug that targets and delivers therapeutic molecules efficiently to specific cell types well beyond traditional liver delivery.

https://www.oligon.com/en
https://www.linkedin.com/company/oligon-inc/

Industry news

ircm-news-2026-03-03

Major financial support awarded by Genome Quebec L’Institut de recherche clinique de Montreal

arena nouvelle - event arn

February 26, 2026

Axelys presents Quebec’s RNA ecosystem to investors at an event in Montreal

January 26, 2026

The RNA Revolution Accelerates: Pharmaceutical and Biotechnology Giants Invest Billions in Next-Generation Therapies

October 15, 2025

Overview of Quebec’s RNA Therapy Sector

press release from moderna on vaccine factory background

September 19, 2025

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

August 19, 2025

The Future of RNA Therapies: Amid Uncertainty, Quebec Emerges as a Hub for RNA Innovation.

August 18, 2025

CASTL Launches Pilot Edition of mRNA/mRNA-LNP Biomanufacturing Training – October 1–3, 2025 | Montreal

martin sauvageau ircm

The IRCM’s Martin Sauvageau talks to Radio-Canada : End of American Funding for mRNA Vaccines

Citeline podcast episode looks at the state of RNA therapeutics with Novotech’s Tom Hickey

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

Interest for RNA Therapy Deals Keeps Growing Among Big Pharmaceuticals

Médicament Québec Awards Two Major Grants for RNA Innovation with Financial Support from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE)

AReNA shines at BIO 2025

Eli Lilly and Company to Acquire Verve Therapeutics for Up to $1.3 Billion

Membres de l'équipe AReNA

AReNA sponsors Rendez-vous Québec at the launch of the BIO International Convention

Pharmaceutiques Magazine spotlights Quebec, driving force for North America’s RNA Sector

DirectIndustry’s take on AReNA, Quebec’s Ambitious Plan to Become a Global RNA Therapeutics Leader

MedicalExpo E-Magazine article highlights AReNA’s panelists at 2025 EFFERVESCENCE on RNA Therapies: From Pandemic Vaccines to Tomorrow’s Medicine.

D2R et AReNA put RNA experts forward at the 92nd ACFAS Congress

effervescence conference 2025

AReNA’s expert panel and networking breakfast energize EFFERVESCENCE conference in Montreal

Panagitos Prinos - Takis photo

Panagiotis Prinos appointed as Director of Réseau DePTAQ

The AReNA breakfast series presents the CELLULE and the RNA valorisation and entrepreneurship team.

CASTL and the DePTAQ Network present their initiative during AReNA’s breakfast event at IRCM

Jean-Pierre Perrault elu recteur de l'UdeS

Jean-Pierre Perreault is elected as Rector of Université de Sherbrooke

Two panelists represent AReNA at Leyton Connect’s 5-to-7

December 19, 2024

AReNA attended FISQ

December 19, 2024

AReNA attends CASTL’s Open Door Day

November 15, 2024

Epitopea closes their $31 million pre-Series A financing.

October 21, 2024

Congratulations to the Nobel Prize winners in Medicine!

September 19, 2024

Congratulations to the 23 recipients of the D2R funding programs

The creation of training programs to meet the needs of the RNA therapeutics industry

The creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

A new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec

Quebec Launches AReNA to Become a Global Leader in RNA Therapies

A group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec

The long-overlooked molecule that will define a generation of science